Three-year and Five-year Outcomes of Surgical Resection for Pancreatic Ductal Adenocarcinoma: Long-term Experiences in One Medical Center
Overview
Authors
Affiliations
Objective: Pancreatic ductal adenocarcinoma is one of the most malignant types of cancer. This study evaluated the 3-year and 5-year surgical outcomes associated with the cancer and determined whether statistically identified factors can be used to predict survival.
Methods: This retrospective review was conducted from 1995 to 2010. Patients who had resectable pancreatic ductal adenocarcinoma and received surgical treatment were included. Cases of hospital mortality were excluded. The relationships between several clinicopathological factors and the survival rate were analyzed.
Results: A total of 223 patients were included in this study. The 3-year and 5-year survival rates were 21.4% and 10.1%, respectively, and the median survival was 16.1 months. Tumor size, N status, and resection margins were independent predictive factors for 3-year survival. Tumor size independently predicted 5-year survival.
Conclusion: Tumor size is the most important independent prognostic factor for 3-year and 5-year survival. Lymph node status and the resection margins also independently affected the 3-year survival. These patient outcomes might be improved by early diagnosis and radical resection. Future studies should focus on the tumor biology of this aggressive cancer.
Qu C, Zeng P, Li C, Hu W, Yang D, Wang H Insights Imaging. 2025; 16(1):38.
PMID: 39962007 PMC: 11833029. DOI: 10.1186/s13244-025-01915-9.
Hirashita T, Tada K, Nagasawa Y, Orimoto H, Kawamura M, Fujinaga A Mol Clin Oncol. 2025; 22(2):18.
PMID: 39776938 PMC: 11704984. DOI: 10.3892/mco.2024.2813.
Khan M, Muhammad S, Mehdi H, Parveen A, Soomro U, Ali J Cureus. 2023; 15(8):e42927.
PMID: 37667689 PMC: 10475154. DOI: 10.7759/cureus.42927.
Mejia A, Shah J, Vivian E, Beard R, Acharya P, Barrera Gutierrez J J Robot Surg. 2022; 17(3):1085-1096.
PMID: 36581740 DOI: 10.1007/s11701-022-01510-w.
Lu L, Shang Y, Zechner D, Mullins C, Linnebacher M, Zhang X Front Psychiatry. 2021; 12:638152.
PMID: 34177643 PMC: 8225995. DOI: 10.3389/fpsyt.2021.638152.